Company intelligence / Profile preview

Y's Therapeutics

Princeton, New Jersey, United Statesymabs.com ↗

Ownership: Private
Employees: ~104
Development stage: Commercial

Overview

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel antibody-based therapies—including radioimmunotherapies—for pediatric and adult cancers. The company has achieved commercial sales with at least one product, with revenues growing from $20M to nearly $88M between 2020–2024. It maintains an advanced pipeline targeting unmet needs in oncology through innovative monoclonal antibodies.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Radioimmunotherapy
Industry: Biotech

Drug pipeline

1 asset

YSIL6

Preclinical

Partnerships

Not specifically named but references to partnerships/collaborations exist for advancing their mission.

Beyond the preview

Go deeper on Y's Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Y's Therapeutics.